A Phase III clinical trial (NCT01377376) investigated the therapeutic efficacy of erlotinib in conjunction with tivantinib in an Asian cohort of patients diagnosed with stage IIIB/IV EGFR wild-type, non-squamous NSCLC (Han et al., 2024). This evidence concerns the gene EGFR and non-small cell lung carcinoma.